이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Outlook Therapeutics 관리

관리 기준 확인 3/4

Outlook Therapeutics' CEO는 Russ Trenary, Jul2021 에 임명되었습니다 의 임기는 2.92 년입니다. 총 연간 보상은 $ 1.76M, 34.1% 로 구성됩니다. 34.1% 급여 및 65.9% 보너스(회사 주식 및 옵션 포함). 는 $ 1.11M 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 1.11M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 5 년입니다.

주요 정보

Russ Trenary

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	34.1%
CEO 임기	2.9yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

CEO 보상 분석

Russ Trenary 의 보수는 Outlook Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$159m
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

보상 대 시장: Russ 의 총 보상 ($USD 1.76M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Russ 의 보상이 증가했습니다.

CEO

Russ Trenary (66 yo)

2.9yrs

테뉴어

US$1,758,862

보상

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ralph Thurman	Independent Executive Chairman	6.2yrs	US$242.50k	0.0025% $ 4.5k
C. Trenary	President	2.9yrs	US$1.76m	0.67% $ 1.2m
Lawrence Kenyon	Executive VP	8.8yrs	데이터 없음	0.0040% $ 7.2k
Jeffrey Evanson	Chief Commercial Officer	5.6yrs	US$718.20k	0.17% $ 306.8k
Alicia Tozier	Senior Vice President	2.3yrs	데이터 없음	데이터 없음
Joel Prieve	Senior Vice President of Licensing and M&A	2.3yrs	데이터 없음	데이터 없음
Surendra Sharma	Senior Vice President of Medical Affairs	1.4yrs	데이터 없음	데이터 없음
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	데이터 없음	데이터 없음
Jedd Comiskey	Senior VP - Head of Europe	less than a year	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: OTLK 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ralph Thurman	Independent Executive Chairman	6.2yrs	US$242.50k	0.0025% $ 4.5k
C. Trenary	President	2.9yrs	US$1.76m	0.67% $ 1.2m
Lawrence Kenyon	Executive VP	5.8yrs	데이터 없음	0.0040% $ 7.2k
Kurt Hilzinger	Independent Director	8.5yrs	US$95.00k	0.10% $ 179.5k
Julia Haller	Independent Director	1.8yrs	US$79.00k	0% $ 0
Julian Gangolli	Independent Non-Employee Director	4.2yrs	US$112.50k	0% $ 0
Arun Pillai	Board Observer	no data	데이터 없음	데이터 없음
Gerd Auffarth	Independent Non-Employee Director	4.2yrs	US$79.00k	0% $ 0
Faisal Sukhtian	Independent Director	6.8yrs	US$113.00k	0.015% $ 25.8k
Yezan Haddadin	Independent Director	6.7yrs	US$110.00k	0.022% $ 38.3k
Andong Huang	Independent Director	4yrs	US$75.00k	0% $ 0

5.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: OTLK 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Outlook Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Recent updates

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics: Likely FDA Approval, Possible Buyout

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial